Roth Capital Downgrades Tonix Pharma (TNXP) to Neutral Citing PTSD Setback

Roth Capital downgraded Tonix Pharma (NASDAQ: TNXP) from Buy to Neutral with a price target of $1.00 (from $6.00).

Analyst Scott Henry cites the disappointing results form the interim Phase 3 review of Tonmya for the downgrade.

For an analyst ratings summary and ratings history on Tonix Pharma click here. For more ratings news on Tonix Pharma click here.

Shares of Tonix Pharma closed at $3.95 yesterday.

You May Also Be Interested In

• Fiserv (FISV) PT Lowered to $60 at Freedom Broker
• Travel Food Services (TRAVELFO:IN) PT Raised to INR1,600 at ICICI Securities
• Sansera Engineering Ltd (SANSERA:IN) PT Raised to INR4,250 at ICICI Securities